Monitoring denosumab therapy using the calcium isotope marker (CIM) technology

Denosumab provides a well-established therapy for osteoporosis. Dual-energy X-ray absorptiometry (DXA) and bone turnover markers (BTMs) track changes in bone mineral density (BMD) and turnover. Calcium (Ca) Isotope Markers (CIM), which measure naturally occurring variations in stable Ca isotope rati...

Full description

Saved in:
Bibliographic Details
Published in:Bone (New York, N.Y.) N.Y.), 2025-09, Vol.198, p.117522, Article 117522
Main Authors: Eisenhauer, Anton, Sönnichsen, Sönke, Hastuti, Agustina, Shroff, Rukshana, Heuser, Alexander, Kolevica, Ana, Lubnow, Amarin, Brandt, Burkard, Müller, Michael
Format: Article
Language:English
Subjects:
Absorptiometry, Photon
Aged
Biomarkers - blood
Biomarkers - urine
Bone Density - drug effects
Bone Density Conservation Agents - therapeutic use
Calcium - blood
Calcium - urine
Calcium Isotopes - blood
Calcium Isotopes - urine
Denosumab - therapeutic use
Female
Humans
Middle Aged
Osteoporosis, Postmenopausal - blood
Osteoporosis, Postmenopausal - drug therapy
Parathyroid Hormone - blood
Pilot Projects
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!